Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza a (h5n1) virus monovalent vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-Influenza A (H5N1)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The influenza A (H5N1) virus monovalent vaccine is an inactivated split-virus biologic developed for the prevention of avian influenza (bird flu). It contains hemagglutinin (HA) from the A/Indonesia/05/2005 strain and was evaluated in clinical trials sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is often administered with the AS03 adjuvant, an oil-in-water emulsion containing squalene, DL-α-tocopherol, and polysorbate 80, which is manufactured by GSK. This adjuvanted formulation is designed to enhance immunogenicity and provide broader cross-protection against heterologous H5N1 strains. The vaccine itself has been manufactured by Sanofi Pasteur and GSK for use in NIAID-led systems biology studies.
- Other names
- H5N1 monovalent vaccineH-5N1 monovalent vaccineH 5N1 monovalent vaccineA/Indonesia/05/2005 vaccineinactivated split-virus H5N1 vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza a (h5n1) virus monovalent vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-Influenza A (H5N1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza a (h5n1) virus monovalent vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-Influenza A (H5N1).